Hepatocellular carcinoma (HCC) is a complex liver malignancy for which a variety of treatment modalities, based on disease stage and patient factors, are available. Traditionally, interventional radiologists (IR) have had a key role in managing intermediate-stage disease through the use of locoregional approaches, while oncologists have employed systemic therapy in the realm of advanced-stage disease. However, an improved understanding of HCC pathology has led to the realization that optimal approaches to selecting, combining, sequencing, and transitioning between different modalities has the potential to improve outcomes across disease settings, underscoring the importance of a multidisciplinary team-based approach to HCC management. As approvals for new drugs (eg, TKIs, anti-angiogenic agents, immunotherapy, combinations) and positive clinical trial outcomes with novel multimodal strategies continue to impact the HCC treatment paradigm, clinical decision-making has become complicated, with many questions arising about optimal approaches to administering various therapies to the appropriate patient in a timely manner within a team-based care model. In this CME-certified online activity, a multidisciplinary panel of interventional radiology, hepatology, and oncology experts offers insights on how to navigate the intermediate- to advanced-stage HCC landscape in an era of evolving treatment—from use of modern IR approaches to newer systemic therapies and combination strategies—to provide the most benefit for patients with HCC.
3975 Fair Ridge Drive • Suite 400 North • Fairfax, Virginia 22033 (703) 691-1805 • Fax (703) 691-1855